193687-88-6

Upstream product

• 503-74-2 3-methylbutyric acid 
• 150-19-6 O-methylresorcine 
• 15116-14-0 2,4-dihydroxyphenyl isobutyl ketone 
• 77-78-1 dimethyl sulfate 
• 590-86-3 isovaleraldehyde 
• 89232-58-6 O-(3-methoxyphenyl)hydroxylamine 
• 10365-98-7 3-methoxyphenylboronic acid 
• 816-66-0 4-methyl-2-oxopentanoic acid 
• 108-12-3 isopentanoyl chloride 
• 462610-98-6 1-(2-((tert-butyldimethylsilyl)oxy)-4-methoxyphenyl)ethan-1-one 
• 552-41-0 1-(2-hydroxy-4-methoxyphenyl)ethanone 
• 462611-02-5 1-[2-(tert-butyl-dimethyl-silanyloxy)-4-methoxy-phenyl]-3-methyl-butan-1-one 
• 20321-73-7 7-methoxy-2,2-dimethyl-4-chromanone 
• 151-10-0 1,3-Dimethoxybenzene 

Downstream Products

• 179630-64-9 5-Methoxy-2-(3-methyl-1-propylsulfanyl-butyl)-phenol 
• 193687-91-1 5-methoxy-2-(3-methyl-1-hydroxybutyl)phenol 

Relevant academic research and scientific papers

RhIII-Catalyzed Decarboxylative o-Acylation of Arenes Bearing an Oxidizing Directing Group

Here in we report, rhodium(III)-catalyzed decarboxylative acylation of arenes using α-oxocarboxylic acids as acyl surrogate. In this strategy, O–NHAc group act as an autocleavable oxidizing directing group (ODGauto), thus giving rise to ortho-acylated phenols in moderate to good yields. Mechanistic studies provided strong support for a kinetically relevant C–H bond activation. According to the best of our knowledge, this is the first report of Rhodium catalyzed decarboxylative acylation.

A Novel Parkinson's Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway

Numerous drug treatments are available for Parkinson's disease (PD), an age-related neurodegenerative disease, but most cause serious side effects. Therefore, novel therapeutic strategies that halt disease progression and allow for long-term administration are urgently needed. Neuroinflammation critically contributes to the pathogenesis of PD. Here, we report the discovery and optimization of phloroglucinol derivatives, a novel class of anti-neuroinflammatory compounds. Structural modifications of the hit compound 3-methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one produced 43 derivatives, including a preclinical candidate (compound 21), that exhibited potent in vitro anti-neuroinflammatory effects, good blood-brain barrier penetration, and desirable safety margins in mice at a median lethal dose (LD50) >5000 mg/kg. Its in vivo efficacy was demonstrated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- and MPTP/probenecid (prob)-induced subacute and chronic PD models, respectively, and α-synuclein transgenic mice. Mechanistic studies revealed neuroinflammation inhibition by targeting Src/phosphatase and tensin homologue deleted on chromosome 10 (PTEN)/Akt signaling might be promising. We highlighted the potential usefulness of phloroglucinol derivatives in PD treatment.

Synthesis of 2-acylphenol and flavene derivatives from the ruthenium-catalyzed oxidative c-h acylation of phenols with aldehydes

The cationic ruthenium hydride complex [(C6H6)(PCy3)(CO)RuH]+BF4- has been found to be an effective catalyst for the oxidative C-H coupling reaction of phenols with aldehydes to give 2-acylphenol compounds. The coupling of phenols with α,β-unsaturated aldehydes selectively gives the flavene derivatives. The catalytic method mediates direct oxidative C-H coupling of phenol and aldehyde substrates without using any metal oxidants or forming wasteful byproducts. A cationic ruthenium hydride complex catalyzes the oxidative C-H coupling of phenols with aldehydes to form 2-acylphenol and flavene derivatives.

Synthesis and biological evaluation of some novel 4H-benzopyran-4-one derivatives as nonsteroidal antiestrogens

The preparation and characterization of some novel 2- and 3-substituted-7-methoxy-4H-1-benzopyran-4-one are presented. The synthesized compounds were evaluated for their uterotrophic, antiuterotrophic and antiimplantation activities in mature female albino rats. 3-Benzyl-7-methoxy-4H-1-benzopyran-4-one (14) showed the highest uterotrophic activity (87%) based on dry uterine weight gain. The antifertility activity, as assessed by the post-coital antiimplantation activity test, was of weak potency for most compounds (14-29%). Among the products, the 2-(4′-methoxyphenyl)-7-methoxy-4H-1-benzopyran-4-one (19) exhibited the highest antiestrogenic activity of 65%. It also elicited 31% of the uterotrophic activity of estradiol.

Synthesis and lipase-mediated stereoselective deacetylation of (±)-3-acetoxymethyl-3-alkyl-7-methoxychroman-4-ones

Six (±)-3-acetoxymethyl-3-alkyl-7-methoxychroman-4-ones have been synthesized in four steps starting with the coupling of resorcinol with corresponding aliphatic acid leading to the formation of 2,4-dihydroxyphenyl alkyl ketones, which upon monomethylation and hydroxymethylation, followed by acetylation afforded the racemic acetoxymethylated compounds in 17-30% overall yields. Candida rugosa lipase-catalyzed deacetylation of (±)-3-acetoxymethylchromanones in diisopropyl ether exhibited fairly moderate enantioselectivity.

Chromenes and chromanones. Part IV.1 The Birch reduction of 2,2-dimethyl-4-chromanone and its 7-substituted analogues

2,2-Dimethyl-4-chromanone (1a), 2,2,7-trimethyl-4-chromanone (1b) and 7-methoxy-2,2-dimethyl-4-chromanone (1c) have been reduced by sodium or lithium in liquid ammonia with the presence or without of proton donor. The bicyclic or phenolic products were obtained. Products with reduced benzene ring only were also observed. The possible mechanisms of reductions are considered.

Electrochemical synthesis of chroman and euglobal skeletons via cycloaddition reaction of o-quinone methides and alkenes

Euglobal skeletons were synthesized by the intermolecular cycloaddition reaction of terpenes and o-quinone methides generated in situ by electrochemical oxidation. In a two-phase reaction medium composed of hexane-lithium perchlorate/nitromethane, 2-[1-(p